Sep 4, 2013 | Coding, Billing, and Collections, Digital Pathology, Laboratory Hiring & Human Resources, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations, News From Dark Daily
As medical laboratories struggle to reduce costs and squeeze their budgets, it is essential that the lab’s quality assurance/quality control program is run properly to protect and enhance the analytical integrity of lab test results
When does budget cutting in a clinical laboratory begin to undermine the accuracy and analytical integrity of the medical laboratory test results produced by the laboratory?
This question is apparently a subject of much discussion within some lab organizations where aggressive cost reduction programs are shrinking lab staff and reducing funds spent on controls and similar QA/QC resources.
(more…)
Jul 15, 2011 | Laboratory News, Laboratory Pathology, Managed Care Contracts & Payer Reimbursement
Document leak earlier this week pulls curtain back on potential cuts to Medicare/Medicaid spending
Spending cuts of between $334 billion and $353 billion over the next 10 years are on the table in the negotiations over the federal debt ceiling. The bad news for the clinical laboratory industry is that restoration of the Medicare patient co-pay for medical laboratory tests is not only on the list of proposed spending cuts, but represents a significant chunk of money—as much as $16 billion during the next decade!
Typical of beltway politics, it was only because of a leak that the list of proposed Medicare and Medicaid spending cuts became public knowledge. On Tuesday this week, Kaiser Health News was one of the first to report the leak of the documents. It also posted a copy of the briefing documents on its website.
(more…)
Mar 22, 2010 | Laboratory News, Laboratory Pathology, News From Dark Daily
Some clinical labs use new pathology lab test technologies to deliver added value to physicians, patients, and payers
Clinical pathology laboratories in the United States and other developed countries across the globe face an unprecedented double-whammy. On one hand, the ongoing explosion of genetic and molecular knowledge gives pathologists and clinical laboratories incredible new tools for diagnosing disease and guiding therapy.
On the other hand, funding for government health programs in the United States and other developed countries is failing to keep pace with demand for health services and the need to pay for all the sophisticated molecular diagnostics and complex therapies now coming to market.
(more…)
